KRRO

Korro Bio (KRRO)

About Korro Bio (KRRO)

Korro Bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of a new class of genetic medicines based on editing RNA. The company was founded by Nessan Bermingham, Jean-Francois B. Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

Details

Daily high

$8.30

Daily low

$7.72

Price at open

$8.05

52 Week High

$55.89

52 Week Low

$5.20

Market cap

74.5M

Dividend yield

0.00%

Volume

145,061

Avg. volume

438,313

P/E ratio

-.84

Korro Bio News